DSIP 10mg (Delta Sleep-Inducing Peptide)

DSIP is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with a molecular weight of 848.8 g/mol, the formula C35H48N10O15, CAS number 62568-57-4 and PubChem CID 68816. It carries an International Nonproprietary Name, emideltide, and the FDA substance identifier YN28Z5YZ73, which is unusual for a compound that was never developed as a drug. The sequence resembles no other known peptide family: it has no basic residue, no cysteine, no amide cap, and its only aromatic residue is the N-terminal tryptophan.

The name records an experiment rather than a mechanism. In Basel between 1963 and 1977, Marcel Monnier and Guido Schoenenberger stimulated the intralaminar thalamic nuclei of rabbits at low frequency to drive them into slow-wave sleep, dialysed the cerebral venous blood leaving those brains, and infused the dialysate into awake recipient animals, which then showed enhanced delta and spindle activity on EEG. The active fraction was purified, sequenced and synthesised, and the 1978 report in Pflugers Archiv named it Delta Sleep-Inducing Peptide. Everything that followed had to live up to a name assigned by a bioassay.

Much of it did not. Nearly fifty years on, no DSIP gene, precursor protein or receptor has been isolated in any species, no study of DSIP is registered on ClinicalTrials.gov, and the sleep literature splits by species, by laboratory and by route. What survived better is a body of work on the stress axis, on opioid-linked withdrawal, on chronobiology and on mitochondrial respiration, plus a large immunohistochemical record of DSIP-like immunoreactivity in tissues that have little to do with sleep regulation. DSIP is supplied here as a research reagent and holds no marketing authorisation in any jurisdiction.

DSIP has no identified receptor. This is not a gap in the summaries, it is a gap in the primary literature: Graf and Kastin wrote in their 1986 update that several mechanisms had been proposed and that no convincing evidence had been obtained for any of them, and Kovalzon and Strekalova restated the same position in the Journal of Neurochemistry twenty years later. A reader should treat every mechanism below as a reproducible pharmacological observation whose molecular target is unknown.

The best characterised of those observations is adrenergic. Graf and Schoenenberger (1987) had found that DSIP reduced the nocturnal rise in N-acetyltransferase activity in the rat pineal gland in a concentration-dependent way. Working in vitro, they then showed that DSIP between 20 and 300 nM significantly enhanced the N-acetyltransferase activity induced by 1 micromolar norepinephrine. Prazosin abolished the enhancement; propranolol reduced the norepinephrine response but left the enhancement by the phosphorylated analogue intact. The reading they gave, and the one that still stands, is that DSIP modulates how the alpha-1 adrenergic receptor of the pineal responds to catecholamines rather than binding a receptor of its own.

The stress axis result is more localised than it is usually reported. Graf, Kastin, Coy and Fischman (1985) gave rats 5 to 30 micrograms per kilogram of DSIP intravenously and measured corticosterone release stimulated by corticotropin releasing factor. Corticosterone fell significantly. When the same animals were given ACTH directly instead of CRF, DSIP did nothing. The peptide therefore acts somewhere between CRF and ACTH, at the level of the pituitary, and does not blunt the adrenal response itself. Elevated plasma DSIP-like immunoreactivity in patients with major depressive disorder, and its relationship to dexamethasone suppression, sit on the same axis.

An opioid arm runs through the older Geneva work and through recent rodent studies. Tissot showed that morphine, alcohol, pentobarbital and DSIP all produced spindle-rich slow-wave activity when injected into the bulbo-mesencephalo-thalamic recruiting system, and that naloxone reversed all four, which is the observation that sent DSIP into withdrawal research. Roy and colleagues (2018) reproduced the naloxone dependence in a modern design: 1 mg/kg naloxone abolished the effect of phosphorylated DSIP on spatial navigation and on hippocampal CREB phosphorylation in rats under simulated altitude. Naloxone sensitivity is evidence of an opioid-pathway dependency, not evidence of direct binding at a mu receptor, and no binding study has closed that distinction.

A fourth line is bioenergetic and does not involve neurotransmission at all. Khvatova and colleagues (2003) measured oxygen consumption polarographically in isolated rat brain mitochondria and found that DSIP raised the rate of phosphorylating respiration (state 3) and the respiratory control ratio while leaving uncoupled respiration unchanged, which is the signature of improved coupling rather than of a stimulant effect. In rats made hypoxic, 120 micrograms per kilogram given intraperitoneally beforehand completely prevented the hypoxia-induced fall in state 3 respiration.

The isolation is worth describing in detail because the whole compound rests on it. Rabbits were implanted for EEG recording and driven into slow-wave sleep by low-frequency electrical stimulation of the intralaminar thalamic nuclei. Their cerebral venous blood was routed through an extracorporeal dialysis circuit, and the dialysate was infused into the ventricles of awake recipient rabbits, which then showed increased delta and spindle activity. Fourteen years of fractionation on that assay ended with a nonapeptide.

The 1978 confirmation paper is a model of what a structure-activity control set should look like. Schoenenberger and colleagues synthesised the nonapeptide together with five plausible metabolic products (fragments 1-8, 2-9, 2-8, 1-4 and 5-9), two nonapeptide analogues with one and two residues exchanged, and the related tripeptide Trp-Ser-Glu that Monnier had made specifically to test whether the N-terminal tryptophan alone was doing the work. All nine peptides were infused at 6 nmol/kg in a CSF-like solution over three and a half minutes and tested double-blind in 61 rabbits including controls, with the EEG from frontal neocortex and limbic archicortex analysed by direct fast Fourier transformation. Only the full-length peptide raised delta activity, by about 35% against vehicle, and the authors reported that only the pure alpha-aspartyl form was highly active while its beta-Asp isomer was not.

That last detail is the most practically useful thing in the paper and it is missing from almost every secondary description. Aspartyl residues rearrange to the beta-linked isomer through a succinimide intermediate, particularly under the base treatments used in Fmoc synthesis and during storage in solution at neutral to alkaline pH. A DSIP preparation that has partially isomerised at Asp5 is chemically almost indistinguishable by mass, since the rearrangement is isobaric, but on the founding assay it is a different compound.

The first serious replication attempt went the other way. Tobler and Borbely (1980) gave rats DSIP systemically at 40 to 160 nmol/kg intraperitoneally and centrally at 7 to 24 nmol into the lateral or third ventricle, and found no significant increase in sleep or in EEG delta-band power in the hours after either. Delta-band power was in fact reduced after 7 nmol into the third ventricle. Their conclusion was that neither DSIP nor arginine vasotocin qualifies as a specific sleep-promoting substance, and it was published two years after the sequence.

Species then split the field. Susic and colleagues (1987) found a clear positive result in cats: 7 nmol/kg into the lateral ventricle of 10 animals shortened sleep latency and increased deep slow-wave sleep by more than half in the first hour, an effect that lasted seven hours and came from longer episodes rather than more of them, with REM sleep untouched. Graf and Kastin's 1984 review had already recorded that the response was mainly delta sleep in rabbits, rats, mice and humans but mainly REM in cats, which is close to the opposite of what Susic measured. Reviews describing a coherent cross-species sleep effect are reading past this.

The human trials that were run were small, and the two best-designed ones concluded against the compound. Monti and colleagues (1987) used a double-blind crossover design with 25 nmol/kg intravenously over four nights in chronic insomnia patients: total sleep time and stage 2 rose, but the same differences were already present at baseline, and the authors judged the improvement to be of little clinical significance. Bes and colleagues (1992) used a double-blind matched-pairs parallel-group design in 16 chronic insomnia patients with the same 25 nmol/kg over three nights, found higher sleep efficiency and shorter latency on polysomnography, and then reported that the effects were weak, that subjective sleep quality was unchanged, and that short-term treatment of chronic insomnia with DSIP was unlikely to be of major therapeutic benefit. Schneider-Helmert's earlier Experientia study, positive in six middle-aged insomnia patients, is the one usually cited and had no placebo arm.

A structural warning sign runs through the whole dataset. Graf and Kastin described a U-shaped activity curve for both the amount infused and the timing of the infusion, meaning the effect appears in a narrow window and vanishes above and below it. A biphasic response is not automatically artefact, but combined with a peptide that is degraded within minutes in blood and an EEG endpoint scored differently in each laboratory, it is exactly the shape that makes a literature irreproducible.

The most interesting result in the whole DSIP literature is that the analogues work better than the parent, and that this was demonstrated by the people most invested in the sleep hypothesis. Kovalzon (2001) screened DSIP and 13 synthetic analogues in electrode-implanted rabbits, injecting into the lateral ventricle and monitoring sleep-wake states polygraphically for 7 to 12 daytime hours against saline in the same animals. DSIP itself and most of the analogues produced no statistically significant change. Two did: [NMeAla2]DSIP and [Pro2]DSIP raised the proportion of slow-wave sleep by 10 to 15%. One, [beta-Ala2]DSIP, significantly suppressed sleep. Several proline-containing analogues, and DSIP itself, raised body temperature slightly.

The pattern points at position 2. Kovalzon, Kalikhevich and Churkina had already reported in 1986 that (D-Trp1)DSIP, made more resistant to aminopeptidases, increased slow-wave sleep by 40% in rabbits at 0.7, 7 and 70 micrograms per kilogram intracerebroventricularly and by 25% intravenously within a narrow 30 to 70 micrograms per kilogram range, while unmodified DSIP had not been found hypnogenic in the same hands. N-methylation, D-substitution and proline all do the same thing chemically, which is to block exopeptidase attack at the N-terminal end of the chain.

The phosphorylated analogue tells the same story quantitatively. Kimura and Inoue (1989) infused 0.5 nmol of P-DSIP intracerebroventricularly over 10 nocturnal hours in unrestrained rats and measured a 22% increase in slow-wave sleep and an 81% increase in paradoxical sleep, driven by more sleep episodes rather than longer ones. The window was sharp: amounts from 0.025 to 25 nmol either side of 0.5 nmol were ineffective. Assayed identically, P-DSIP was five times as potent as DSIP.

Graf, Saegesser and Schoenenberger (1987) supplied the reason. Incubating DSIP in human or rat blood released products that eluted from a gel filtration column at the retention time of free tryptophan, with the rate depending on temperature, time and species. Radioiodinated N-Tyr-DSIP and N-Tyr-P-DSIP both degraded more slowly than DSIP, and the labelled analogues formed complexes that unlabelled peptide could not displace, which the authors read as non-specific binding or aggregation rather than receptor occupancy. Rapid disappearance of DSIP from blood is degradation; the longer persistence of the analogues is a mix of slower cleavage and carrier association.

Kovalzon and Strekalova took the argument to its conclusion in 2006. If DSIP itself is not reliably hypnogenic but certain analogues are, and if a naturally occurring dermorphin decapeptide sharing five of the nine positions promotes slow-wave sleep in rabbits while its optical isomer suppresses it, then the endogenous molecule responsible for the original dialysate activity may not be DSIP at all. Their hypothesis is that a distinct DSIP-like peptide accounts for both the immunoreactivity and the biology, and that DSIP is a partially correct guess at its sequence.

Antisera raised against DSIP detect material throughout the body, and where they detect it is the strongest argument against the sleep hypothesis. Charnay and colleagues (1989) mapped DSIP-like immunoreactivity through the rabbit brain and found it concentrated in the basal forebrain, hypothalamus and hypophysis: cell bodies scattered in the ventrolateral septum, diagonal band of Broca and preoptic areas, clusters in the arcuate nucleus, dense fibre networks in the median eminence and pituitary stalk lying against the capillaries, and immunoreactivity in most cells of the pars intermedia. That is the anatomy of a neurosecretory system feeding the portal circulation, not the anatomy of a sleep switch.

Skagerberg, Bjartell, Vallet and Charnay (1991) repeated the mapping in rat diencephalon and hit a problem that has never been resolved. Varicose immunoreactive fibres ran throughout the mediobasal hypothalamus, most densely in the arcuate nucleus, median eminence and pituitary stalk, with further labelling near the third ventricle and in the mamillary complex. But despite colchicine pretreatment, which blocks axonal transport specifically so that peptide accumulates in the soma and becomes visible, no immunoreactive cell bodies could be found at all. The antibody sees the terminals of a system whose cells of origin it cannot see.

No DSIP gene, mRNA or precursor has ever been isolated, in rabbit or in any other species. The one sequence match that turned up is unhelpful in an interesting way: comparative transcriptomics of circadian oscillating genes identified the protein annotated as delta sleep-inducing peptide immunoreactor as glucocorticoid-induced leucine zipper (GILZ), a transcription factor that reciprocally regulates adipogenic and osteogenic differentiation in stromal stem cells and oscillates in adipose tissue. GILZ is a real gene with real circadian and glucocorticoid biology, and it is not a nonapeptide. It is a good illustration of how an immunoreactivity-defined entity can drift away from the molecule that named it.

The clinical correlations were nonetheless reproducible enough to publish repeatedly. Ernst and colleagues (1987) measured DSIP-like and phosphorylated DSIP-like immunoreactivity by radioimmunoassay in cerebrospinal fluid and found both rose with age in controls and fell significantly relative to age-matched controls in middle and late Alzheimer type dementia, multi-infarct dementia, Parkinson's disease, vascular disease and communicating hydrocephalus, while the phosphorylated form showed no pathology-related differences. Van Kammen and colleagues (1992) found CSF DSIP-like immunoreactivity in 15 drug-free men with schizophrenia correlated with stage 3 sleep and with delta sleep in the first NREM period, and negatively with the proportion of stage 2. Westrin, Ekman and Traskman-Bendz (1998) found significantly elevated plasma DSIP-like immunoreactivity in 34 suicide attempters with major depressive disorder, with predexamethasone cortisol and DSIP-like immunoreactivity correlated in healthy controls.

By the mid 1980s the centre of gravity had already moved off sleep. The withdrawal work came out of Geneva and followed directly from Tissot's observation that morphine, alcohol, pentobarbital and DSIP all produced spindle-rich slow-wave activity in the bulbo-mesencephalo-thalamic recruiting system and that naloxone reversed all four. Dick, Grandjean and Tissot (1983) gave 25 nmol/kg of DSIP intravenously as sole treatment to 67 patients in alcohol or opiate withdrawal, of whom 49 were evaluable, and reported benefit in 48 with immediate onset on somatic signs and slower resolution of anxiety. Dick and colleagues extended this to 107 inpatients in 1984, 47 in alcohol withdrawal and 60 in opiate withdrawal, with roughly 13% and 22% respectively not evaluable, reporting marked improvement in 97% and 87% and headache as the only notable complaint.

Those numbers need to be read for what the design was. Both studies were open-label, with outcome judged clinically by the treating physicians and nursing staff, no placebo arm, no blinding and no standardised withdrawal scale. Withdrawal syndromes resolve on their own over the same timescale. The results are a reason the question stayed open, not an answer to it.

The chronobiology thread is smaller but more distinctive. Schneider-Helmert (1984) gave repeated DSIP injections to a single 35-year-old man with narcolepsy and found the frequency of sleep attacks fell while daytime activity, alertness and performance rose, with the sleep period compressed and REM enhanced. The interpretation offered was not sedation at all but an accentuation of circadian and ultradian rhythms, which is a different claim from the one the compound is named for and fits the observation that DSIP modulates pineal N-acetyltransferase, the rate-limiting enzyme of nocturnal melatonin synthesis. Repeated administration of DSIP and its analogues also shifted circadian locomotor patterns in rats.

Longevity and tumour work has been reported from Russian groups using the DSIP-based preparation Deltaran. Female SHR mice given five-day monthly courses at 5 micrograms per kilogram over their lifespan showed a 16% longer survival in the most aged decile, more vertical activity in the open field from six months onward, 73% more time in the open arms of the elevated plus maze, and slowed spontaneous carcinogenesis. This work has not been replicated outside the originating group and should be weighted accordingly.

DSIP is chemically simple and analytically awkward in specific ways. Its only chromophore is Trp1, so a single tryptophan carries the entire 280 nm absorbance of the molecule: quantification by UV is straightforward, but oxidation of that one indole side chain, which light and peroxide-containing solvents both promote, changes both mass and detection response. With no lysine, arginine or histidine in the chain and two carboxylate side chains plus the free C-terminus, the peptide is acidic and freely water soluble, and it will not behave like the cationic peptides most laboratories handle by default on cation exchange resins.

Asp5 is the residue that matters for identity. The isobaric rearrangement to the beta-aspartyl form proceeds through a succinimide intermediate, is accelerated at neutral to alkaline pH and by heat, and is invisible to a mass measurement because the isomers weigh the same. Since Schoenenberger's group reported that only the alpha form was highly active in the rabbit EEG assay, a certificate of analysis that establishes mass and gross purity does not by itself establish that a batch is the active isomer. Reversed-phase HPLC can resolve the two if the method is developed for it.

Biostability in blood is measured rather than estimated. Graf, Saegesser and Schoenenberger (1987) incubated DSIP in human and rat blood and followed the appearance of products with the gel filtration retention time of free tryptophan, with degradation dependent on temperature, time and species. The rapid disappearance of injected DSIP from circulation is enzymatic cleavage, most of it aminopeptidase attack on the N-terminal end, which is precisely what D-Trp1, N-methyl-Ala2 and Pro2 substitution were designed to obstruct. Radiolabelled analogues additionally formed complexes that excess unlabelled peptide could not displace, consistent with non-specific binding to plasma components rather than a saturable site.

For laboratory storage the practical implications follow from the chemistry rather than from any peptide-specific study: the lyophilized powder is the stable form and belongs at minus 20 degrees Celsius in the dark and dry, solutions belong at 2 to 8 degrees Celsius and are the state in which both tryptophan oxidation and aspartyl isomerisation proceed, and repeated freeze-thaw cycling is worth avoiding on a peptide whose bioassay history is this sensitive to preparation.

DSIP is often shelved next to Epithalon because both trace to sleep and pineal biology, but the two are different kinds of object. Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, 390.35 g/mol, designed by Khavinson's group as the minimal active fragment of a pineal extract, with a proposed mechanism at telomerase transcription. DSIP is a nonapeptide isolated from blood on an EEG endpoint, with no synthetic design rationale and no proposed transcriptional target. Their only real point of contact is the pineal gland, and there the relationship is indirect: DSIP modulates N-acetyltransferase, the rate-limiting enzyme in melatonin synthesis, through an alpha-1 adrenergic mechanism.

The comparison with Selank and Semax is more instructive because those two show what a well-supported neuropeptide record looks like. Both are rationally designed from a known parent, tuftsin and ACTH(4-7) respectively, both carry a deliberate Pro-Gly-Pro stabilising tail, both have named mechanistic anchors that were measured directly, and both have a registered pharmaceutical form in Russia. DSIP has none of that. It has an accidental discovery, an unresolved receptor question, an open sequence question, and a set of analogues that outperform it.

Against melatonin, which is the comparison buyers most often reach for, DSIP is not in the same category at all. Melatonin is an indoleamine hormone with two identified G protein-coupled receptors, MT1 and MT2, an established synthetic pathway from serotonin, and a defined circadian release profile. DSIP is a peptide with none of those things. The one point where their biology touches is the pineal N-acetyltransferase step that DSIP was shown to modulate, which makes DSIP upstream of melatonin production in rat pineal preparations rather than a substitute for it.